Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
5 hedge funds and large institutions have $18.7K invested in Anthera Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 24 closing their positions.
82% less funds holding
Funds holding: 28 → 5 (-23)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 24
97% less capital invested
Capital invested by funds: $621K → $18.7K (-$602K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$44.5K |
| 2 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
+$1.6K |
| 3 |
SMFS
Squar Milner Financial Services
Irvine,
California
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$143K |
| 2 |
Renaissance Technologies
New York
|
-$132K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$129K |
| 4 |
VF
Virtu Financial
New York
|
-$50K |
| 5 |
Goldman Sachs
New York
|
-$37K |
ANTH Hedge Fund Activity: Q2 2018 in Review
5 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q2 2018, worth a combined $18.7K — down 97% from $621K a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ANTH and 1 opened new positions — a net loss of 23 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Wedbush Securities, adding an estimated $44.5K. The largest seller was Vanguard Group, exiting entirely with an estimated $143K sold.
- 5 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q2 2018, down from 28 in Q1 2018.
- Funds reported $18.7K of Anthera Pharmaceuticals, Inc. stock for Q2 2018, down 97% quarter-over-quarter.
- 1 fund opened new Anthera Pharmaceuticals, Inc. positions in Q2 2018 and 24 closed out, a net change of -23 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q2 2018 was Wedbush Securities, an estimated $44.5K added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q2 2018 was Vanguard Group, an estimated $143K sold.
Based on aggregated 13F filings for Q2 2018.